Ellipticine is an established anticancer chemotherapeutic, however, its current method of synthesis requires many steps. MUSC researchers have developed a method to obtain ellipticine analogs in one step by utilizing radiation and an acid catalysis. The ellipticine family represents a class of natural products that have been used to develop potential treatments for cancer, HIV, and malarial infection. Recent communications have described rapid access approaches toward quninone4 and aza5 analogs from a common indoline core.
The invention provides for a novel approach of treating lung fibrosis related diseases (including scleroderma lung disease, idiopathic pulmonary fibrosis, interstitial pneumonia, asbestosis). Currently, there are no effective treatments available for these diseases. Upregulation of caveolin-1 was achieved by either infecting cells with adenovirus encoding the full-length caveolin-1 molecule or using a membrane-permeable peptide containing the caveolin-1 scaffolding domain (CSD). Control bleomycin-treated mice showed severe lung damage, whereas mice receiving CSD showed only slight ...
Commercially available devices for vagus nerve stimulation are implantable devices, requiring an invasive and expensive procedure. MUSC researchers are developing a noninvasive device that stimulates the vagus system incorporating ear electrodes with optimized pulses that can be tailored based on the condition to be treated (epilepsy, depression, stroke, tinnitus, etc.). This device is currently undergoing testing at MUSC (n=15) in order to show direct brain effects as investigated by functional magnetic resonance imaging.
Inventors at MUSC have developed a high-quality, packaged, e-learning module for goniometry applicable to physical and occupational therapy that incorporates multi-media (audio & video), interactive text, goal setting, and documentation. The modules cover goniometry for upper extremities and lower extremities including elbow, hand, scapula, shoulder, thumb, and wrist. Each extremity is further divided into specific flexions, such as adduction, abduction, and internal and external rotation, for which content is presented.
Lunch & Learn Session: An Easier Way to Provide & Access Novel Research Reagents
Thursday, September 22, 2016 - 12:00pm to 1:00pm
Colbert Education Center and Library Room 109
This is an information session explaining how to facilitate access to lab-made reagents, including antibodies, cell lines, proteins, tissues and more.
Enjoy a free lunch!
Interested in attending? RSVP to Christine Dixon at firstname.lastname@example.org
Neuroene Therapeutics Awarded $225,000 STTR Research Grant
Startup rooted in MUSC investigators’ efforts to find new anti-seizure drugs
Charleston, S.C. (Aug. 24, 2016) – Neuroene Therapeutics, a startup company born from unique research by two Medical University of South Carolina (MUSC) investigators, secured a Small Business Technology Transfer (STTR) grant for $225,000 in July from the National Institute of Neurological Disorders and Stroke (NINDS).
Neuroene Therapeutics is using the Phase I STTR grant to help further develop a novel class of compounds for treating epilepsy. In the U.S. alone, epilepsy’s estimated direct and indirect costs total $15.5 billion, according to the Health and Medicine Division of the National Academies of Sciences.
SCTR/FRD Technology Development Grants - Apply Today!
The primary objective of these awards is to support projects that have a high chance of being commercialized, but that are not likely to get there without gap funding. Funds are intended to advance projects to the next developmental milestone by enabling investigators to conduct additional experiments, such as those that:
• Optimize compounds
• Conduct toxicology studies
• Help define a pharmacological target or translational biomarker
• Test a therapeutic against a new indication
• Prototype a device
• Build or validate a software program
Pre-Application Due: September 15, 2016
Contact: Ford Simmons - email@example.com
MUSC, Harbor Entrepreneur Center to launch life-science tech accelerator in Charleston
Charleston’s growing medical technology industry will be the focus of a new accelerator program launching this fall.
The program, called PriMed, aims to give a boost to startups that make products like medicines and medical devices when it takes in its first group of companies in September.
The initiative is a collaboration between the Harbor Entrepreneur Center, which runs an accelerator for traditional tech startups, and the Medical University of South Carolina’s Foundation for Research Development, which helps make the school’s inventions commercially available.
FRD Welcomes Two New Board Members
The MUSC Foundation for Research Development (FRD) welcomes two new board members. These two new members exemplify innovation and development and will be a great asset to the Foundation. Welcome!
Dr. Robert D. McQuade
Ph.D. | Biochemistry, UNC
Currently Executive Vice President and Chief Strategic Officer at Otsuka Pharmaceuticals Development and Commercialization.
Dr. Paul Williamson
M.D | University of Massachusetts
MUSC Start-Up Wins Prestigious National Award
Congratulations to ToleRaM Nanotech, LLC for winning a National TechConnect Innovation Award, which is meant to recognize innovative technology that has the potential to make a difference in a special sector, such as medicine. Only 15% of submitted entries receive the prestigious award.
Click here for more information.
Charleston Celebrates Entrepreneurship
We had a great turnout at the "Charleston Celebrates Entrepreneurship" event on Friday, April 22nd. Speakers included Dr. Cam Patterson from New York-Presbyterian Hospital/Weill Cornell Medical Center, and MUSC's very own Dr. Bart Sachs. Mayor John Tecklenberg reinforced his commitment to entrepreneurial growth here in Charleston.
SCTR Technology Development Grant Awardees
Congratulations to Nathan Dolloff, Ph.D. and James Chou, Ph.D. on receiving the most recent SCTR technology development grants.
James Chou, Ph.D.'s research focus is centered around the neuro-vitamin K (VK) synthase UBIAD1, which has recently been identified through a forward genetic screen as a dominant enhancer of the Parkinson’s disease (PD) establishing an additional link among mitochondria, vitamin K, and PD pathogenesis. Supplementation of VK reverses the non-flight phenotype observed in the drosophila model. Unfortunately, for humans, neuronal VK requires a series of metabolic processes and direct synthesis by UBIAD1 in the central nervous system in situ, and cannot be supplemented through dietary means. We have developed VK analogs that can easily penetrate blood-brain barrier and showed effective in the chemical induced PD model. The SCTR-FRD Grant will allow the optimization of the lead drug candidate’s dosing routine instead of performing the costly efficacy experiments blindly. With the funded study, it will also significantly move the project forward for future efficacy studies.